Key Metrics of Torrent Pharmaceuticals
Revenue₹10,712 Cr▲ 10.6% YoYFY 2025-26
EBITDA₹4,002 Cr▲ 11.7% YoY
Net profit₹2,192 Cr▲ 16.1% YoY
Net worth₹8,452 Cr▲ 11.3% YoY
Competitors10identified
About Torrent Pharmaceuticals
Sectors
Company details
- Website
- torrentpharma.com
- Founded
- 1959
- Registered office
- Avirat, Thaltej Shilaj Road, Shilaj, Daskroi, Ahmedabad, In-gj, 380059
- Listed
- NSE: TORNTPHARM · ₹4,613.40
Operational Areas of Torrent Pharmaceuticals
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Pharmaceuticals & Healthcare›Large Pharma Companies
Pharmaceuticals & Healthcare›State-wise Pharma Manufacturers
Pharmaceuticals & Healthcare›APIs & Bulk Drugs
Pharmaceuticals & Healthcare›Generic Formulations
Company summary
Entity details
CINL24230GJ1972PLC002126
LEI code335800NA6HK275RIJE13
State codeGJ
PIN code380059
Current legal nameTORRENT PHARMACEUTICALS
Classification—
Listing statusListed (NSE: TORNTPHARM)
Registration no.002126
Company age67 years, 9 months
PAN—
CountryIndia
CityAhmedabad
StateGujarat
Current statusActive
Date of incorporation01 Jan 1959
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—
Compliance
Last AGM date—
Last balance sheet—
Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026
Industry classification
NIC code24230
Description of main activityManufacture of chemicals and chemical products (incl. pharmaceuticals)
Description of business activityManufacture of chemicals and chemical products (incl. pharmaceuticals)
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Premium
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
AGM for FY 2025-2630 Sep 2026
Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026
Statutory due date · 0 days left
MGT-7 for FY 2025-2629 Nov 2026
Statutory due date · 29 days left
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
ICRA · 21 Jul 2026
—
Other
Change in last 12 months—
Change since first rating on record—since Jul 2026
Rating actions10 up · 0 down
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 21 Jul 2026 | ICRA | Other | — | — | — | — | View |
Agency-reported financials (ICRA, 21 Jul 2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
| Operating income | ₹11,516 Cr | ₹13,980 Cr |
| PAT | ₹1,911 Cr | ₹2,138 Cr |
| OPBDIT/OI | 32.3% | 32.6% |
| PAT/OI | 16.6% | 15.3% |
| Total outside liabilities/Tangible net worth (times) | 0.90× | 1.50× |
| Total debt/OPBDIT (times) | 0.90× | 3.30× |
| Interest coverage (times) | 14.70× | 11.80× |
| Revenue growth (YoY) | — | 21.4% |
| EBITDA (margin × income) | ₹3,720 Cr | ₹4,557 Cr |
| Implied total debt (debt/EBITDA × EBITDA) | ₹3,348 Cr | ₹15,039 Cr |
| Implied interest cost (EBITDA ÷ coverage) | ₹253 Cr | ₹386 Cr |
Borrowings & rated debt
Rated borrowing limits (latest)—
Limits raised0 times0 new facilities rated
Weighted average coupon7.66%
Debt instruments
| ISIN | Instrument | Type | Coupon | Issued | Maturity | Amount | Rating | Status |
|---|---|---|---|---|---|---|---|---|
| INE685A07132 | NCD Jan Jan | Debentures & bonds | 7.45% | — | — | ₹2,000 Cr | AA+ | Not stated |
| INE685A07157 | NCD Jan Jan | Debentures & bonds | 7.60% | — | — | ₹2,490 Cr | AA+ | Not stated |
| INE685A07165 | NCD Jan Jan | Debentures & bonds | 7.70% | — | — | ₹3,000 Cr | AA+ | Not stated |
| INE685A07173 | NCD Jan Jan | Debentures & bonds | 7.80% | — | — | ₹3,500 Cr | AA+ | Not stated |
| INE685A14187 | Commercial Paper Jan Dec + | Commercial paper | 7.20% | — | — | ₹1,500 Cr | AA+ | Not stated |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26
Indicative long-term—
Indicative short-term—
Score—
LiquidityStretched
DirectionStable
ICRA rating · Jul 2026—
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 52% |
| Information on file | 67% · missing: Capex / investment plans, Lender details, Auditor details |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
Can it borrow more?Further bank funding difficult
Next rating action stable or better: 52% (At risk of downgrade) · ML model on 4072 rating histories, AUC 0.666
Rated limits—
Not yet allocated—
Extra debt within 2.5× EBITDA—
Interest coverage11.80×
Limit utilisation—
Open bank charges0 · —
- Credit outlook model: 52% chance the next rating action is stable or better
- Interest coverage 11.8×
Rated limits by facility
Timeline
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Registered officeAVIRAT, THALTEJ SHILAJ ROAD, SHILAJ, DASKROI, AHMEDABAD, IN-GJ, 380059
GSTIN—
Email—
Websitehttp://www.torrentpharma.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Torrent Pharmaceuticals
Competitors10identified
Locations3most in India
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
 Dr. Reddy's Laboratories |
Part of Dr. Reddy's Laboratories. | drreddys.com | 1984 | India |
 Aurobindo Pharma |
Part of Aurobindo Pharma. | aurobindo.com | 1986 | Hyderabad, India |
 Cipla |
Part of Cipla. | cipla.com | 1935 | Mumbai, India |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lupin.com | 1968 | India | |
 Glenmark Pharmaceuticals |
Part of Glenmark Pharmaceuticals. | glenmarkpharma.com | 1977 | Mumbai, India |
| Part of Biocon. | biocon.com | 1978 | Bangalore, India | |
 Alkem Laboratories Limited |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | alkemlabs.com | 1973 | Mumbai, Maharashtra, India |
| Aster DM Quality Care Limited | Discovered Companies · Other Industries | — | — | Hyderabad, Telangana, India |
 Thomas Cook India |
Part of Thomas Cook Group. | thomascook.in | 1978 | Mumbai, India |
 Divi's Laboratories |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | divislabs.com | 1990 | Hyderabad, India |
Similar companies
C
CiplaPharmaceuticals & Healthcare
Same segment: Generic Formulations · Similar revenue scale · Close financial profile
L
Lupin Ltd.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Similar revenue scale · Close financial profile
D
Dr. Reddy's LaboratoriesPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Similar revenue scale · Close financial profile
A
Ajanta Pharma LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Close financial profile
G
Granules India LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Close financial profile
A
Alembic Pharmaceuticals LtdPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Similar revenue scale · Close financial profile
K
Kwality Pharmaceuticals LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Close financial profile
I
Indoco Remedies LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Close financial profile
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.